Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Letter
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0443
Abstract: Patel and colleagues report the results of the basket trial (DART) studying the checkpoint inhibitors combination, ipilimumab plus nivolumab, in a cohort of patients with neuroendocrine neoplasms (NEN; ref. [1][1]). We commend the authors for… read more here.
Keywords: s1609 neuroendocrine; neuroendocrine letter; rare tumors; ipilimumab nivolumab ... See more keywords